Condition: Renal Cell Carcinoma · Urothelial Carcinoma · Castration-resistant Prostate Cancer · Sponsor: Deciphera Pharmaceuticals, LLC
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
This description comes directly from the study's public registry record.
Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt- Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology, Austin | Austin, Texas, United States | Recruiting |
| NEXT Oncology, San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06966024